en.Wedoany.com Report on Mar 26th, Insilico Medicine announced on the Hong Kong Stock Exchange on March 26 that it has entered into an expanded AI-driven R&D collaboration with Tenacia Biotechnology (Hongkong) Co., Limited ("Tenacia Biotechnology"). According to the agreement, both parties will leverage generative artificial intelligence technology to jointly develop an innovative candidate molecule with specific attributes for challenging neurological diseases and advance it to the preclinical candidate stage to address differentiated clinical needs.
The total transaction value for this expanded collaboration could reach up to $94.75 million. Under the terms of the agreement, Insilico Medicine is expected to receive upfront and milestone payments from Tenacia Biotechnology. This collaboration represents a further deepening of the partnership between the two parties in the field of AI-driven drug discovery, demonstrating Tenacia Biotechnology's continued recognition of the technical capabilities of Insilico Medicine's AI drug discovery platform.
Insilico Medicine is a globally leading AI-driven drug discovery company, with its self-developed end-to-end AI drug discovery platform covering the entire process from target identification, molecule generation to clinical outcome prediction. The company has previously established collaborations with multiple international pharmaceutical companies, advancing several AI-discovered candidate molecules into clinical stages. Tenacia Biotechnology focuses on drug research and development for central nervous system (CNS) diseases, dedicated to addressing unmet clinical needs in neurological disorders.
Neurological diseases have long been a high-risk area for new drug development due to their complex pathogenesis and difficult target validation. Insilico Medicine's generative AI platform can rapidly generate innovative molecular structures with specific attributes through massive data mining and deep learning, potentially significantly improving the efficiency and success rate of new drug R&D in the CNS field. This collaboration deeply integrates Insilico Medicine's AI molecule generation capabilities with Tenacia Biotechnology's R&D experience in the CNS field to jointly advance the clinical translation of innovative therapies.
Insilico Medicine stated that this collaboration demonstrates the application potential of its AI platform in the CNS field, and the company will continue to expand R&D collaborations with global pharmaceutical companies in the future to advance more AI-discovered candidate molecules into clinical stages. Tenacia Biotechnology indicated that through the deep collaboration with Insilico Medicine, it expects to accelerate the R&D process of innovative therapies for CNS diseases, bringing more treatment options to patients.
